ONC001 is a first-in-class antibody-drug conjugate (ADC) designed to uniquely target CD64, a myeloid-restricted receptor pervasively expressed in CMML and M4/M5 acute myeloid leukemia, including ...

Two new antibodies may treat autoimmune diseases by reducing inflammation through blocking the immune receptor FcγRI.

An international research group directed by UMC Utrecht has developed and characterized two first-in-class antibodies that ...

Several European biotechs, including Cellbox Labs, Evotec SE, Nanolive SA, and Salipro Biotech AB, have developed innovative ...

Mitochondrial DNA (mtDNA) exhibits a degree of resistance to mutagenesis under genotoxic stress, and this study on the mitochondrial Transcription Factor A (TFAM) presents valuable data concerning the ...

NEW YORK, Nov. 3, 2025 /PRNewswire/ -- The DeGregorio Family Foundation with support from the Torrey Coast Foundation has awarded a $750,000 Michael F. Price Memorial Grant to Eric Smith, MD, PhD, and ...

An international research group directed by UMC Utrecht have developed and characterized two first-in-class antibodies that ...

The targeted radiotherapies for cancer market is experiencing significant growth, driven by advancements in technology and investment. The cancer radiotherapy market, particularly the radioligand ...

Molecular glues are revolutionizing cancer therapy by targeting undruggable proteins for degradation, enhancing precision ...

A new study has revealed how a natural compound in our cells can reverse brain deficits in animal models of Alzheimer’s disease. The research shows that boosting levels of a molecule called NAD+ ...

The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet To view an enhanced version of this graphic, please visit: ...

UNIGE scientists reveal how separase, a key enzyme in cell division, ensures the accurate separation of chromosomes. Schematic representation of how separase (in pink and purple in the background) ...